Table I.
Patient characteristics.
| EGFR mutation (%) | |||
|---|---|---|---|
| Characteristics | Mutant (n=15) | Wild type (n=49) | |
| Age | |||
| Median, range | 61, 52–72 | 60, 34–74 | |
| Gender | |||
| Male | 10 (67) | 38 (78) | |
| Female | 5 (33) | 11 (22) | |
| Smoking status | |||
| Non-smoker | 8 (53) | 6 (12) | |
| Current/former smoker | 7 (47) | 43 (88) | P<0.001 |
| ECOG-PS | |||
| 0–1 | 15 (100) | 49 (100) | |
| 2–4 | 0 | 0 | |
| Clinical stage | |||
| IIIA | 7 (47) | 22 (45) | |
| IIIB | 8 (53) | 27 (55) | |
| Chemotherapy regimen | |||
| Platinum based regimen | 15 (100) | 49 (100) | |
| Presence of EGFR-TKI therapy | 15 (100) | 3 (0.12) | P<0.0001 |
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.